Assessment of the potential of phage-antibiotic synergy to induce collateral sensitivity in Salmonella Typhimurium

Microb Pathog. 2023 Jul:180:106134. doi: 10.1016/j.micpath.2023.106134. Epub 2023 May 5.

Abstract

This study was designed to evaluate the synergistic effect of phage and antibiotic on the induction of collateral sensitivity in Salmonella Typhimurium. The synergistic effects of Salmonella phage PBST32 combined with ciprofloxacin (CIP) against S. Typhimurium KCCM 40253 (STKCCM) were evaluated using a fractional inhibitory concentration (FIC) assay. The CIP susceptibility of STKCCM was increased when combined with PBST32, showing 16-fold decrease at 7 log PFU/mL. The combination of 1/2 × MIC of CIP and PBST32 (CIP[1/2]+PBST32) effectively inhibited the growth of STKCCM up to below the detection limit (1.3 log CFU/mL) after 12 h of incubation at 37 °C. The significant reduction in bacterial swimming motility was observed for PBST32 and CIP[1/4]+PBST32. The CIP[1/4]+PBST32 increased the fitness cost (relative fitness = 0.57) and decreased the cross-resistance to different classes of antibiotics. STKCCM treated with PBST32 alone treatment exhibited the highest coefficient of variation (90%), followed by CIP[1/4]+PBST32 (75%). These results suggest that the combination of PBST32 and CIP can be used to control bacterial pathogens.

Keywords: Bacteriophage; Cross resistance; Fluctuation; Phage-antibiotic synergy; Relative fitness; Swimming motility.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteriophages*
  • Ciprofloxacin / pharmacology
  • Drug Collateral Sensitivity
  • Drug Resistance, Multiple, Bacterial
  • Microbial Sensitivity Tests
  • Salmonella typhimurium*

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin